Evidence map›Paper›PMID 41266582›Full record

ArticleCommunications biology2025

Characterization of the bone marrow architecture of multiple myeloma using spatial transcriptomics.

Emma Muiños-Lopez, Ana Rosa Lopez-Perez, Laura Sudupe, Amaia Vilas-Zornoza, Sarai Sarvide, Purificacion Ripalda-Cemborain, Paula Aguirre-Ruiz, Patxi San Martin-Uriz, Marta Larrayoz, Laura Alvarez-Gigli and 19 more

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Emma Muiños-Lopez *Hematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Navarra, Spain. emuinos@unav.es.ORCID http://orcid.org/0000-0002-6618-4135
Ana Rosa Lopez-Perez *Translational Bioinformatics Unit, Navarrabiomed, Universidad Pública de Navarra (UPNA), Pamplona, Navarra, Spain.
Laura Sudupe *Bioscience Program, Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.
Amaia Vilas-ZornozaHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Navarra, Spain.
Sarai SarvideHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Navarra, Spain.
Purificacion Ripalda-CemborainHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Navarra, Spain.
Paula Aguirre-RuizHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Navarra, Spain.
Patxi San Martin-UrizHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Navarra, Spain.ORCID http://orcid.org/0000-0003-1483-4279
Marta LarrayozHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Navarra, Spain.
Laura Alvarez-GigliDepartament of Pathology, Clinica Universidad de Navarra (CUN), Pamplona, Spain.
Marta Abengozar-MuelaDepartament of Pathology, Clinica Universidad de Navarra (CUN), Pamplona, Spain.
Itziar CenzanoHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Navarra, Spain.ORCID http://orcid.org/0000-0002-9030-3069
Miguel CóceraHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Navarra, Spain.
Javier RuizHospital Universitario de Navarra, Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain.
Ignacio SanchoHospital Universitario de Navarra, Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain.
Azari BantanBioscience Program, Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.
Aleksandra KurowskaBioscience Program, Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.ORCID http://orcid.org/0000-0001-5950-0358
Jin YeHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Navarra, Spain.
Phillip T NewtonDepartment of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-2142-1798
Bruno PaivaHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Navarra, Spain.
Luis Esteban Tamariz-AmadorHematology and Cell Therapy Department. Cancer Center Clinica Universidad de Navarra (CCUN), IdiSNA, Pamplona, Spain.
Juan R Rodriguez-MadozHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Navarra, Spain.ORCID http://orcid.org/0000-0003-4327-1866
Vincenzo LaganiBioscience Program, Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.ORCID http://orcid.org/0000-0002-6552-6076
Jesper TegnerBioscience Program, Biological and Environmental Sciences and Engineering Division (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.ORCID http://orcid.org/0000-0002-9568-5588
Borja SaezHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Navarra, Spain.
Jose Angel Martinez-ClimentHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Navarra, Spain.ORCID http://orcid.org/0000-0002-7938-3950
Isabel A CalvoHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Navarra, Spain. icalvoa@unav.es.ORCID http://orcid.org/0000-0001-6619-4571
David Gomez-CabreroTranslational Bioinformatics Unit, Navarrabiomed, Universidad Pública de Navarra (UPNA), Pamplona, Navarra, Spain. david.gomezcabrero@kaust.edu.sa.ORCID http://orcid.org/0000-0003-4186-3788
Felipe ProsperHematology and Oncology Program, Centre for Applied Medical Research (CIMA), Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Cancer Center Clinica Universidad de Navarra (CCUN), Pamplona, Navarra, Spain. fprosper@unav.es.ORCID http://orcid.org/0000-0001-6115-8790

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The bone marrow (BM) is a complex and compartmentalized tissue where spatial context plays a critical role in regulating cell behavior, signaling, and disease progression. To capture these dynamics, we apply spatial transcriptomics using the Visium Spatial Gene Expression platform on formalin-fixed paraffin-embedded (FFPE) BM sections from both healthy and Multiple Myeloma (MM) mouse models, as well as MM patient samples. Overcoming the technical challenges of working with mineralized long bone tissue, we develop a custom analytical framework integrating spatial and single-cell transcriptomic data to map cellular composition and interactions in situ. This approach enables the spatial characterization of transcriptionally heterogeneous malignant plasma cells (MM-PC) and their surrounding microenvironments. We identify spatially distinct gene programs linked to MM pathogenesis, including signatures of NETosis and IL-17 signalling, which are reduced in MM-PC-rich regions. Additionally, a transition gradient from effector to exhausted T cell phenotype is associated with increased remoteness from MM-PC. These spatial patterns are identified in FFPE BM biopsies from MM patients with varying tumor burdens. In summary, our study demonstrates both the capabilities and limitations of Visium technology in characterizing spatially regulated mechanisms underlying MM pathogenesis.

Indexed as

Bone MarrowMultiple MyelomaTranscriptomeAnimalsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiceSingle-Cell AnalysisTumor Microenvironment

Identifiers

PMID41266582
PMCPMC12634688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.